Internal medicine

Pathology

Placebo

Enzalutamide

Androgen

Castration

Antiandrogen

Prostate cancer

Androgen receptor

Cancer

Urology

Oncology

Alternative medicine

Androgen deprivation therapy

Hormone

Medicine

New England Journal of Medicine

Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression–free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer